ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally. Meet the Supercharged Growth Stock That Could Join Apple ...

Soon, a new nasal spray may be replacing it in certain cases. “Anyone who has experienced or witnessed an anaphylaxis ...

In a pivotal development this year, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) in August 2024 for emergency use in type 1 allergic reactions, such as anaphylaxis.

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to ...

The nasal spray, dubbed neffy, has been filed for use in adults and children weighing 30 mg or more as an alternative to epinephrine injections such as Kaléo’s AUVI-Q and Viatris’ EpiPen ...

ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

(NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, except in the U.S., Australia, New Zealand, Japan, and China. In August ...

TUESDAY, Oct. 8, 2024 (HealthDay News) --- The recent approval of a new epinephrine nasal spray gives patients a powerful new way to keep life-threatening allergic reactions at bay. But that doesn ...

New Needle-Free Epinephrine Nasal Spray a ‘Game Changer’The FDA has approved a nasal spray, called neffy, to treat serious allergic reactions in adults and children who weigh at least 66 pounds.